Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC)

Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC)

Objective: The main aim of the study was to evaluate the efficacy and safety profile of Nivolumab, an immune-checkpoint-inhibitor antibody, in advanced, previously treated, Non-Small Cell Lung Cancer (NSCLC) patients, in a real world setting. Methods: We performed a retrospective, multicentre data a...

Full description

Bibliographic Details
Main Authors: A. Figueiredo, M.A. Almeida, M.T. Almodovar, P. Alves, A. Araújo, D. Araújo, F. Barata, L. Barradas, A. Barroso, U. Brito, E. Camacho, D. Canário, T. Cardoso, A. Chaves, L. Costa, J. Cunha, J. Duarte, F. Estevinho, M. Felizardo, J.P. Fernandes, L. Ferreira, P. Fidalgo, C. Freitas, P. Garrido, N. Gil, D. Hasmucrai, E. Jesus, J.A. Lopes, J.E. de Macedo, A. Meleiro, R. Neveda, F. Nogueira, M. Pantorotto, B. Parente, A. Pego, M. Rocha, J. Roque, C. Santos, J. Saraiva, E. Silva, S. Silva, S. Simões, M. Soares, E. Teixeira, T. Timóteo, V. Hespanhol
Format: Article
Language:English
Published: Elsevier España 2020-01-01
Series:Pulmonology
Online Access:http://www.sciencedirect.com/science/article/pii/S2531043719301266

Internet

http://www.sciencedirect.com/science/article/pii/S2531043719301266

Similar Items